258 related articles for article (PubMed ID: 25863582)
1. Meta-analyses of randomized controlled trials show suboptimal validity of surrogate outcomes for overall survival in advanced colorectal cancer.
Ciani O; Buyse M; Garside R; Peters J; Saad ED; Stein K; Taylor RS
J Clin Epidemiol; 2015 Jul; 68(7):833-42. PubMed ID: 25863582
[TBL] [Abstract][Full Text] [Related]
2. Surrogate end points for median overall survival in metastatic colorectal cancer: literature-based analysis from 39 randomized controlled trials of first-line chemotherapy.
Tang PA; Bentzen SM; Chen EX; Siu LL
J Clin Oncol; 2007 Oct; 25(29):4562-8. PubMed ID: 17876010
[TBL] [Abstract][Full Text] [Related]
3. Progression-Free Survival and Time to Progression as Real Surrogate End Points for Overall Survival in Advanced Breast Cancer: A Meta-Analysis of 37 Trials.
Li L; Pan Z
Clin Breast Cancer; 2018 Feb; 18(1):63-70. PubMed ID: 28818493
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of tumor response, disease control, progression-free survival, and time to progression as potential surrogate end points in metastatic breast cancer.
Burzykowski T; Buyse M; Piccart-Gebhart MJ; Sledge G; Carmichael J; Lück HJ; Mackey JR; Nabholtz JM; Paridaens R; Biganzoli L; Jassem J; Bontenbal M; Bonneterre J; Chan S; Basaran GA; Therasse P
J Clin Oncol; 2008 Apr; 26(12):1987-92. PubMed ID: 18421050
[TBL] [Abstract][Full Text] [Related]
5. Individual- and trial-level surrogacy in colorectal cancer.
Buyse M; Burzykowski T; Michiels S; Carroll K
Stat Methods Med Res; 2008 Oct; 17(5):467-75. PubMed ID: 18285439
[TBL] [Abstract][Full Text] [Related]
6. Combining tumour response and progression free survival as surrogate endpoints for overall survival in advanced colorectal cancer.
Elia EG; Städler N; Ciani O; Taylor RS; Bujkiewicz S
Cancer Epidemiol; 2020 Feb; 64():101665. PubMed ID: 31911395
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of progression-free survival as a surrogate endpoint for survival in chemotherapy and targeted agent metastatic colorectal cancer trials.
Sidhu R; Rong A; Dahlberg S
Clin Cancer Res; 2013 Mar; 19(5):969-76. PubMed ID: 23303214
[TBL] [Abstract][Full Text] [Related]
8. Progression-free Survival as a Surrogate End-point in Advanced Colorectal Cancer Treated with Antiangiogenic Therapies.
Montagnani F; DI Leonardo G; Pino MS; Martella F; Perboni S; Ribecco A; Fioretto L
Anticancer Res; 2016 Aug; 36(8):4259-65. PubMed ID: 27466541
[TBL] [Abstract][Full Text] [Related]
9. Progression-free survival is a surrogate for survival in advanced colorectal cancer.
Buyse M; Burzykowski T; Carroll K; Michiels S; Sargent DJ; Miller LL; Elfring GL; Pignon JP; Piedbois P
J Clin Oncol; 2007 Nov; 25(33):5218-24. PubMed ID: 18024867
[TBL] [Abstract][Full Text] [Related]
10. Surrogacy of intermediate endpoints for overall survival in randomized controlled trials of first-line treatment for advanced soft tissue sarcoma in the pre- and post-pazopanib era: a meta-analytic evaluation.
Tanaka K; Kawano M; Iwasaki T; Itonaga I; Tsumura H
BMC Cancer; 2019 Jan; 19(1):56. PubMed ID: 30634944
[TBL] [Abstract][Full Text] [Related]
11. Progression-free survival as a surrogate for overall survival in first-line chemotherapy for advanced pancreatic cancer.
Hamada T; Nakai Y; Isayama H; Yasunaga H; Matsui H; Takahara N; Mizuno S; Kogure H; Matsubara S; Yamamoto N; Tada M; Koike K
Eur J Cancer; 2016 Sep; 65():11-20. PubMed ID: 27451020
[TBL] [Abstract][Full Text] [Related]
12. The value of surrogate endpoints for predicting real-world survival across five cancer types.
Shafrin J; Brookmeyer R; Peneva D; Park J; Zhang J; Figlin RA; Lakdawalla DN
Curr Med Res Opin; 2016; 32(4):731-9. PubMed ID: 26743800
[TBL] [Abstract][Full Text] [Related]
13. Alternative end points to evaluate a therapeutic strategy in advanced colorectal cancer: evaluation of progression-free survival, duration of disease control, and time to failure of strategy--an Aide et Recherche en Cancerologie Digestive Group Study.
Chibaudel B; Bonnetain F; Shi Q; Buyse M; Tournigand C; Sargent DJ; Allegra CJ; Goldberg RM; de Gramont A
J Clin Oncol; 2011 Nov; 29(31):4199-204. PubMed ID: 21969501
[TBL] [Abstract][Full Text] [Related]
14. Progression-free survival as a surrogate endpoint for median overall survival in metastatic colorectal cancer: literature-based analysis from 50 randomized first-line trials.
Giessen C; Laubender RP; Ankerst DP; Stintzing S; Modest DP; Mansmann U; Heinemann V
Clin Cancer Res; 2013 Jan; 19(1):225-35. PubMed ID: 23149819
[TBL] [Abstract][Full Text] [Related]
15. Progression-Free Survival as a Surrogate for Overall Survival in Clinical Trials of Targeted Therapy in Advanced Solid Tumors.
Michiels S; Saad ED; Buyse M
Drugs; 2017 May; 77(7):713-719. PubMed ID: 28337673
[TBL] [Abstract][Full Text] [Related]
16. A Comparison of Response Patterns for Progression-Free Survival and Overall Survival Following Treatment for Cancer With PD-1 Inhibitors: A Meta-analysis of Correlation and Differences in Effect Sizes.
Gyawali B; Hey SP; Kesselheim AS
JAMA Netw Open; 2018 Jun; 1(2):e180416. PubMed ID: 30646078
[TBL] [Abstract][Full Text] [Related]
17. Progression-Free Survival as a Surrogate End Point for Overall Survival in First-Line Diffuse Large B-Cell Lymphoma: An Individual Patient-Level Analysis of Multiple Randomized Trials (SEAL).
Shi Q; Schmitz N; Ou FS; Dixon JG; Cunningham D; Pfreundschuh M; Seymour JF; Jaeger U; Habermann TM; Haioun C; Tilly H; Ghesquieres H; Merli F; Ziepert M; Herbrecht R; Flament J; Fu T; Coiffier B; Flowers CR
J Clin Oncol; 2018 Sep; 36(25):2593-2602. PubMed ID: 29975624
[TBL] [Abstract][Full Text] [Related]
18. Progression-free survival and time to progression as surrogate markers of overall survival in patients with advanced gastric cancer: analysis of 36 randomized trials.
Shitara K; Ikeda J; Yokota T; Takahari D; Ura T; Muro K; Matsuo K
Invest New Drugs; 2012 Jun; 30(3):1224-31. PubMed ID: 21350803
[TBL] [Abstract][Full Text] [Related]
19. Progression-free survival and one-year milestone survival as surrogates for overall survival in previously treated advanced non-small cell lung cancer.
Zhao S; Zhang Z; Zhang Y; Hong S; Zhou T; Yang Y; Fang W; Zhao H; Zhang L
Int J Cancer; 2019 Jun; 144(11):2854-2866. PubMed ID: 30430561
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
